SEC Tracker
Get the app

Keros Therapeutics KROS

OrbiMed Genesis Master Fund (Shareholder) plans to sell 45,057 KROS shares, about $497,429

Form
144
Filed
Importance
Routine
  1. Approximate sale date: Mar 31, 2026
  2. Broker: Themis Trading LLC
  3. Shares acquired by: IPO

All of OrbiMed Genesis Master Fund's insider filings, holdings and planned sales

Written from the Form 144 on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when Keros Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Zevra Therapeutics ZVRA public float $455M, Jun 30, 2025
  2. Theravance Biopharma TBPH public float $449M, Jun 30, 2025
  3. aTYR PHARMA ATYR public float $464M, Jun 30, 2025
  4. Arvinas ARVN public float $469M, Jun 30, 2025
  5. Arbutus Biopharma ABUS public float $472M, Jun 30, 2025